Stockreport

Ipsen's Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis [Yahoo! Finance]

GENFIT S.A. - American Depositary Shares  (GNFT) 
PDF Approval based on positive Phase III ELATIVE trial data Primary biliary cholangitis impacts approximately 100,000 people in the US and is growing in global prevalence [Read more]